Curatis identifies potential drug candidates for a repurposing development approach in indications with high unmet medical needs via its extensive network within the scientific and medical community, as well as within the biotech/pharmaceutical industry. Curatis invests a significant portion of its revenues and resources in its development activities.

The current pipeline is a balance of preclinical and clinical compounds with clinically validated targets.


Molecule Pre-clinical Phase I Phase II Phase III Market
C-H-01 prevention of frequent episodic tension type headache
C-M-01 prevention of severe migraine with aura

*Amyotrophic lateral sclerosis